Navigation Links
Tobacco makes medicine
Date:3/18/2009

Tobacco isn't famous for its health benefits. But now scientists have succeeded in using genetically modified tobacco plants to produce medicines for several autoimmune and inflammatory diseases, including diabetes. The research is published in the open access journal BMC Biotechnology.

A large team of scientists from several European research organizations have participated in the study as part of the Pharma-Planta project (http://www.pharma-planta.org/). Led by Professor Mario Pezzotti at the University of Verona, they set out to create transgenic tobacco plants that would produce biologically-active interleukin-10 (IL-10), a potent anti-inflammatory cytokine. They tried two different versions of IL-10 (one from a virus, one from the mouse) and generated plants in which this protein was targeted to three different compartments within the cell, to see which would work most effectively.

The researchers found that tobacco plants were able to process both forms of IL-10 correctly, producing the active cytokine at high enough levels that it might be possible to use tobacco leaves without lengthy extraction and purification processes. The next step will be to feed the plants to mice with autoimmune diseases to find out how effective they are.

The authors are keen to use the plants to see whether repeated small doses could help prevent type 1 diabetes mellitus (T1DM), in combination with other auto-antigens associated with the disease. The team has a particular auto-antigen in its sights the 65-kDa isoform of the enzyme glutamic acid decarboxylase (GAD65) which they have also produced in transgenic tobacco plants.

According to Pezzotti, "Transgenic plants are attractive systems for the production of therapeutic proteins because they offer the possibility of large scale production at low cost, and they have low maintenance requirements. The fact that they can be eaten, which delivers the drug where it is needed, thus avoiding lengthy purification procedures, is another plus compared with traditional drug synthesis."


'/>"/>

Contact: Charlotte Webber
charlotte.webber@biomedcentral.com
44-207-631-9980
BioMed Central
Source:Eurekalert

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
3. Your babys brain on drugs (and alcohol and tobacco)
4. UT researchers find link between advertising and increased tobacco use among Indias youth
5. Infection blocks lungs protective response against tobacco smoke
6. Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants
7. New drug makes weight loss safer
8. How mother of thousands makes plantlets
9. For honey bee queens, multiple mating makes a difference
10. Scientists spy enzyme that makes us unique
11. Thinking makes it so: Science extends reach of prosthetic arms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2020)... ... March 05, 2020 , ... With numerous ... with Phoenestra GmbH to accelerate Cytonus’ existing products and to expand the companies’ ... Phoenestra is a biotech company located in Austria. , Phoenestra has developed ...
(Date:3/5/2020)... ... 05, 2020 , ... Diagenode, a leading global provider of ... subsidiary of global genomics leader BGI Group, today announced a co-marketing agreement for ... Asia Pacific. , Under the terms of the non-exclusive agreement, the two ...
(Date:3/4/2020)... ... March 04, 2020 , ... The Massachusetts Medical ... the MedTech IGNITE program’s 2020 IGNITE Cohort. The MedTech IGNITE Program is a ... nurture the next generation of medtech founders and entrepreneurs. IGNITE Cohort members get ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... and LA JOLLA, Calif. (PRWEB) , ... March 31, 2020 , ... ... and La Jolla Institute for Immunology (LJI), announced today that they will use Carterra’s ... CoVIC to move therapeutic candidates to the clinic as early as this summer. , ...
(Date:3/19/2020)... FREDERICK, Md. (PRWEB) , ... ... ... announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit ... gene-modified cell therapies for ovarian cancer and other solid tumor indications. The ...
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader of ... its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing format ... on ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. The ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will make ... The company will showcase both expanded and emerging offerings that align with the HIMSS ... is designed to be comprehensive, timely, and engaging. From Interoperability and HIE ...
Breaking Biology Technology: